Mayo MASS和R2-ISS分期系统在初诊多发性骨髓瘤患者中的预后价值验证：单中心研究

OBJECTIVE: To evaluate the prognostic value of Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma（MM）. METHODS: A total of 371 patients newly diagnosed with MM in Jiangsu Province Hospital were included in the study. Cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization（cIg-FISH）was performed to detect cytogenetic abnormality. Clinical characteristics were combined to analyze the disease stage and evaluate the prognosis. RESULTS: There were 37（10.0％）, 264（71.0％）, and 70（18.8％）patients in R-ISS stage Ⅰ, Ⅱ, and Ⅲ, respectively. The median progression-free survival（PFS）times were 37, 25, and 14 months（P<0.001）. The median overall survival（OS）times were not reached（NR）, 66, and 30 months（P<0.001）. There were 71（19.1％）, 140（37.7％）, and 160（43.2％）patients in Mayo MASS stages Ⅰ, Ⅱ, and Ⅲ, and the median PFS times periods were 43, 27, and 19 months（P<0.001）, and the median OS times were NR, NR, 35 months, respectively（P<0.001）. There were, 23（6.2％）, 69（18.6％）, 222（59.8％）, and 57（15.4％）patients in R2-ISS stages Ⅰ, Ⅱ, Ⅲ, and Ⅳ, respectively. The median PFS times were 47, 31, 25, and 15 months（P＝0.001）, and the median OS times were NR, NR, 49, and 55 months, respectively（P<0.001）. CONCLUSION: Based on the R-ISS staging system, Mayo MASS, and R2-ISS prognostic staging system incorporated 1q21+, which allows a better stratification. However, the proportion of stage Ⅲ patients in Mayo MASS and R2-ISS staging systems is relatively high, which is considered related to the high incidence of 1q21+ and ISS Ⅲ in the Chinese population.